Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Cisplatin is widely used for treating various solid tumors. However, this drug produces dose-limiting ototoxicity and nephrotoxicity, which significantly reduce the quality of life of cancer patients. While nephrotoxicity could be alleviated by diuresis, there is currently no approved treatment for hearing loss. Previous studies show that the ROS and inflammation are major contributors to cisplatin-induced hearing loss. In this study, we show that ROS trigger the inflammatory process in the cochlea by activating signal transducer and activator of transcription-1 (STAT1). Activation of STAT1 activation was dependent on ROS generation through NOX3 NADPH oxidase, knockdown of which by siRNA reduced STAT1 activation. Moreover, STAT1 siRNA protected against activation of p53, reduced apoptosis, reduced damage to OHCs and preserved hearing in rats. STAT1 siRNA attenuated the increase in inflammatory mediators, such as TNF-α, inhibition of which protected cells from cisplatin-mediated apoptosis. Finally, we showed that trans-tympanic administration of etanercept, a TNF-α antagonist, protected against OHC damage and cisplatin-induced hearing loss. These studies suggest that controlling inflammation by inhibition of STAT1-dependent pathways in the cochlea could serve as an effective approach to treat cisplatin ototoxicity and improve the overall quality of life for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
Receptor-Dependent Mechanisms of Cell Stimulation by Bacterial Endotoxin
Ulevitch, R. J., & Tobias, P. S. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.002253 · Cited by 1,442
Nox3, a superoxide-generating nadph oxidase of the inner ear
Bánfi, B., Malgrange, B., Knisz, J., Steger, K., Dubois-Dauphin, M., & Krause, K.-H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403046200 · Cited by 467 · cited 3×
“Cisplatin ototoxicity is mediated, in part, by ROS produced through NOX3.”
BackgroundSignal transduction of inflammatory cytokines and tumor development
Yoshimura, A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00197.x · Cited by 314 · cited 1×
“apoptosis, such as Fas, TNF-related apoptosis-inducing ligand (TRAIL) and caspases.(16) STAT1 also mediates cell apoptosis by cisplatin in coordination with the cell-cycle regulator p53.”
BackgroundKang, T.-H., Lindsey-Boltz, L. A., Reardon, J. T., & Sancar, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915085107 · Cited by 250 · cited 1×
“The rapid activation of STAT1 by cisplatin contrasts with the slower pace of induction of DNA-repair enzymes, such as xeroderma pigmentosium A (XPA), by this drug.(30)”
Background
Cited by
Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals
Prasad, S., Gupta, S. C., & Tyagi, A. K. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.03.042 · Cited by 978
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity
Karasawa, T., & Steyger, P. S. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.06.012 · Cited by 475
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Hato, S. V., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3141 · Cited by 451
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Adenosine Receptors: Expression, Function and Regulation
Sheth, S., Brito, R., Mukherjea, D., Rybak, L., & Ramkumar, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022024 · Cited by 401
Self-citation
Metadata
- Authors
- Kaur, T., Mukherjea, D., Sheehan, K., Jajoo, S., Rybak, L. P., & Ramkumar, V
- Venue
- Cell Death & Disease
- Published
- 2011-07-21
- Volume
- 2
- Issue
- 7
- Pages
- e180-e180
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2038528969
- Cited by
- 146
- References
- 5
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.